EFFICACY OF VACCINE PREVENTION OF HPV-ASSOCIATED DISEASES AND CERVICAL CANCER IN THE MOSCOW REGION

Cover Page


Cite item

Full Text

Abstract

Data on high prevalence of papilloma virus infection and associated disorders in adults as well as in adolescents are becoming more and more frequently published in the world and domestic literature. The most severe outcome of the infection is cervical cancer which takes the second place in women of reproductive age. At present, the armamentarium of obstetricians, gynecologists, pediatricians and oncologists is enriched by a recombinant vaccine protecting against human papilloma virus and representing one of effective methods of prevention of HPV-associated disorders. There are two prophylactic vaccines in the world (quadrivalent Gardasil® and bivalent Cervarix®), which are used in 44 countries. One of the first results proving efficacy of vaccination is a decrease of incidence of anogenital warts that is well described in foreign literature. In the Moscow region, as a result of vaccination performed from 2008 to 2013, a decrease of incidence of anogenital warts in girls is also observed.

About the authors

V. I. Krasnopol'skiy

Moscow Regional Scientific Research Institute for Obstetrics and Gynecology

Email: fake@neicon.ru

MD, PhD, Academician of Russian Academy of Sciences, Director

Russian Federation

L. S. Logutova

Moscow Regional Scientific Research Institute for Obstetrics and Gynecology

Email: fake@neicon.ru

MD, PhD, Professor, Deputy Director on Research

Russian Federation

N. V. Zarochentseva

Moscow Regional Scientific Research Institute for Obstetrics and Gynecology

Email: fake@neicon.ru

MD, PhD, Leading Research Fellow, Department of Gynecologic Endocrinology

Russian Federation

Yu. M. Belaya

Moscow Regional Scientific Research Institute for Obstetrics and Gynecology

Author for correspondence.
Email: belajay@yandex.ru

PhD, Chief Specialist of the Ministry of Healthcare of the Moscow Region on pediatric gynecology, Research Fellow, Out-patient Department

Russian Federation

G. V. Tamazyan

Ministry of Healthcare of Moscow Region

Email: fake@neicon.ru

MD, PhD, Deputy Minister of Healthcare of the Moscow Region, Head of Department of Organization of Medical Care to Mothers and Children

Russian Federation

A. L. Gridchik

Ministry of Healthcare of Moscow Region

Email: fake@neicon.ru

MD, PhD, Head of Section in the Department of Organization of Medical Care to Mothers and Children

Russian Federation

References

  1. Башмакова МА, Савичева АМ. Вирусы папилломы человека и их роль в образовании опухолей. М.: Медицинская книга; Н. Новгород: НГМА; 1999. 16 с. (Bashmakova MA, Savicheva AM. Human papilloma viruses and their role in tumorigenesis. Moscow: Meditsinskaya kniga; Nizhny Novgorod: NGMA; 1999. 16 p. Russian).
  2. Бебнева ТН, Прилепская ВН. Папилломавирусная инфекция и патология шейки матки. Гинекология. 2001;3(3):77–81. (Bebneva TN, Prilepskaya VN. [Papillomaviral infection and cervical pathology]. Ginekologiya. 2001;3(3):77–81. Russian).
  3. Каприн АД, Старинский ВВ, Петрова ГВ. Состояние онкологической помощи населению России в 2013 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России; 2014. 235 с. (Kaprin AD, Starinskiy VV, Petrova GV. Status of oncology care to the population of Russia in 2013. Moscow: FGBU “MNIOI im. P.A. Gertsena” Minzdrava Rossii; 2014. 235 p. Russian).
  4. Ван Крог Г, Лейси Д, Гросс Г, Баррассо Р, Шнайдер А. Европейский курс по заболеваниям, ассоциированным с ВПЧ: рекомендации для врачей общей практики по диагностике и лечению аногенитальных бородавок. Инфекции, передаваемые половым путем. 2001;(1):5–13. (von Krogh G, Lacey C, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect. 2000;76(3):162–8).
  5. Ершов ФИ, Киселев ОИ. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЭОТАР-Медиа; 2005. 368 c. (Ershov FI, Kiselev OI. Interferons and their inducers (from molecules to medicines). Moscow: GEOTAR-Media; 2005. 368 p. Russian).
  6. Киселев ВИ. Вирусы папилломы человека в развитии рака шейки матки. М.: Димитрейд График Групп; 2004. 180 с. (Kiselev VI. Human papilloma viruses in cervical cancerogenesis. Moscow: Dimitreyd Grafik Grupp; 2004. 180 p. Russian).
  7. Киселев ВИ, Киселев ОИ. Вирусы папилломы человека в развитии рака шейки матки. СПб. – М.: Роза мира; 2003. 184 c. (Kiselev VI, Kiselev OI. Human papilloma viruses in cervical cancerogenesis. Saint Petersburg – Moscow: Roza mira; 2003. 184 p. Russian).
  8. Минкина ГН. Вакцинопрофилактика рака шейки матки и других заболеваний, ассоциированных с папилломавирусной инфекцией. Эпидемиология и вакцинопрофилактика. 2007;(6):47–51. (Minkina GN. [Vaccine prophylaxis of cervical cancer and other disorders associated with human papilloma virus infection]. Epidemiologiya i vaktsinoprofilaktika. 2007;(6):47–51. Russian).
  9. Роговская СИ. Вакцины против вируса папилломы человека: новые возможности профилактики цервикального рака. Гинекология. 2007;(1):15–20. (Rogovskaya SI. [Vaccines against human papilloma virus: new opportunities for cervical cancer prevention]. Ginekologiya. 2007;(1):15–20. Russian).
  10. Роговская СИ. Папилломавирусная инфекция у женщин и патология шейки матки. М.: ГЭОТАР-Медиа; 2014. 192 c. (Rogovskaya SI. Papillomaviral infection in women and cervical pathology. Moscow: GEOTAR-Media; 2014. 192 p. Russian).
  11. WHO Weekly epidemiological report. 2009, April 10; 84(15):117–32. Available from: http://www.who.int/wer/2009/wer8415/en/
  12. . Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet. 2009;374:301–14.
  13. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, DeCarvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-ofstudy analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Krasnopol'skiy V.I., Logutova L.S., Zarochentseva N.V., Belaya Y.M., Tamazyan G.V., Gridchik A.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies